Boston Scientific Announces Schedule of Events at TCT Scientific Symposium Boston Scientific Corporation (NYSE: BSX) releases the schedule of its major events and product-related clinical research for the Cardiovascular...

NATICK, Mass. , Nov. 1, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) releases the schedule of its major events and product-related clinical research for the Cardiovascular Research Foundation's (CRF) 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, scheduled for November 7 - 11 in San Francisco . TCT is designed to provide new insights for physicians who treat patients with cardiovascular disease and other vascular health issues.

"Among the anticipated clinical results, we particularly look forward to presenting primary endpoint data from the EVOLVE trial, which is evaluating the performance of the SYNERGY™ Stent, our fourth-generation drug-eluting coronary stent platform," said Keith D. Dawkins , M.D., Senior Vice President and Chief Medical Officer for Boston Scientific's Cardiology, Rhythm and Vascular Group. "The SYNERGY Stent is designed to combine the acute performance advantages of the platinum chromium PROMUS Element™ Stent with an innovative bioabsorbable drug-polymer combination engineered to create an ultra-thin, uniform coating that is designed to reabsorb within four months, leaving only a bare-metal stent in the treated vessel."

Schedule of Events (All times are Pacific time, with events to be held at the Moscone Center unless otherwise indicated.)

Tuesday, November 8

Wednesday, November 9

Thursday, November 10

Friday, November 11

Boston Scientific will present its latest drug-eluting stent, peripheral intervention and imaging technologies at booth #1617 in the Exhibit Hall November 8-10 from noon to 5 p.m.

In the U.S., the SYNERGY Stent, PROMUS Element Stent, WATCHMAN Device, Lotus Valve System and TruePath CTO Device are investigational devices and are limited by applicable law to investigational use only and are not available for sale. The safety and efficacy of the Company's drug-eluting stents have not been established in patients with left main or three-vessel disease.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com .

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, product performance, competitive offerings and growth strategies. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

SOURCE Boston Scientific Corporation